{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:17:34Z","timestamp":1790957854890,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R21 AR071623"],"award-info":[{"award-number":["R21 AR071623"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016787","name":"Penn Center for Musculoskeletal Disorders","doi-asserted-by":"publisher","award":["P30-AR050950-10"],"award-info":[{"award-number":["P30-AR050950-10"]}],"id":[{"id":"10.13039\/100016787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes &amp; Diseases"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.gendis.2020.02.004","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T20:22:01Z","timestamp":1583180521000},"page":"38-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Therapeutic potential of TNF\u03b1 inhibitors in chronic inflammatory disorders: Past and future"],"prefix":"10.1016","volume":"8","author":[{"given":"Hongtao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7484-8800","authenticated-orcid":false,"given":"Yejia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.gendis.2020.02.004_bib1","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","article-title":"An endotoxin-induced serum factor that causes necrosis of tumors","volume":"72","author":"Carswell","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.gendis.2020.02.004_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","article-title":"II. Contribution to the knowledge of sarcoma","volume":"14","author":"Coley","year":"1891","journal-title":"Ann Surg"},{"issue":"5996","key":"10.1016\/j.gendis.2020.02.004_bib3","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/312724a0","article-title":"Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin","volume":"312","author":"Pennica","year":"1984","journal-title":"Nature"},{"issue":"5573","key":"10.1016\/j.gendis.2020.02.004_bib4","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1126\/science.1071924","article-title":"TNF-R1 signaling: a beautiful pathway","volume":"296","author":"Chen","year":"2002","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.gendis.2020.02.004_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ijc.2910340219","article-title":"Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice","volume":"34","author":"Haranaka","year":"1984","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.gendis.2020.02.004_bib6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00011-013-0633-0","article-title":"TNF-alpha signalling and inflammation: interactions between old acquaintances","volume":"62","author":"Zelova","year":"2013","journal-title":"Inflamm Res"},{"issue":"4","key":"10.1016\/j.gendis.2020.02.004_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ijcp.12382","article-title":"Anti-TNF-\u03b1 therapy for patients with sepsis: a systematic meta-analysis","volume":"68","author":"Lv","year":"2014","journal-title":"Int J Clin Pract"},{"issue":"8","key":"10.1016\/j.gendis.2020.02.004_bib8","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s00018-003-2347-x","article-title":"Tumor necrosis factor \u03b1 in the pathogenesis of cerebral malaria","volume":"60","author":"Gimenez","year":"2003","journal-title":"Cell Mol Life Sci"},{"issue":"20","key":"10.1016\/j.gendis.2020.02.004_bib9","doi-asserted-by":"crossref","first-page":"13964","DOI":"10.1074\/jbc.M601553200","article-title":"Interactions of tumor necrosis factor (TNF) and TNF receptor family members in the mouse and human","volume":"281","author":"Bossen","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gendis.2020.02.004_bib10","first-page":"309","article-title":"Creation of mouse TNFR2-selective agonistic TNF mutants using a phage display technique","volume":"7","author":"Ando","year":"2016","journal-title":"Biochem Biophys Rep"},{"issue":"2","key":"10.1016\/j.gendis.2020.02.004_bib11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1073\/pnas.95.2.570","article-title":"The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor","volume":"95","author":"Grell","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.gendis.2020.02.004_bib12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.gendis.2020.02.004_bib13","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.immuni.2013.01.012","article-title":"Endothelial TNF receptor 2 induces IRF1 transcription factor-dependent interferon-beta autocrine signaling to promote monocyte recruitment","volume":"38","author":"Venkatesh","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib14","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/s41419-018-1266-6","article-title":"Differential roles of TNFalpha-TNFR1 and TNFalpha-TNFR2 in the differentiation and function of CD4(+)Foxp3(+) induced Treg cells in\u00a0vitro and in\u00a0vivo periphery in autoimmune diseases","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.gendis.2020.02.004_bib15","doi-asserted-by":"crossref","first-page":"e0175207","DOI":"10.1371\/journal.pone.0175207","article-title":"The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study","volume":"12","author":"Moots","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.gendis.2020.02.004_bib16","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2015-207613","article-title":"A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study","volume":"76","author":"Bae","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.gendis.2020.02.004_bib18","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor Antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.gendis.2020.02.004_bib19","first-page":"139","article-title":"Remicade((R)) (infliximab): 20 years of contributions to science and medicine","volume":"13","author":"Melsheimer","year":"2019","journal-title":"Biologics"},{"issue":"15","key":"10.1016\/j.gendis.2020.02.004_bib20","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.gendis.2020.02.004_bib21","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.gendis.2020.02.004_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.gie.2005.08.011","article-title":"Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease","volume":"63","author":"Rutgeerts","year":"2006","journal-title":"Gastrointest Endosc"},{"issue":"22","key":"10.1016\/j.gendis.2020.02.004_bib23","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"issue":"9194","key":"10.1016\/j.gendis.2020.02.004_bib24","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.gendis.2020.02.004_bib25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2010.135111","article-title":"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept","volume":"70","author":"Jamnitski","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gendis.2020.02.004_bib26","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.14309\/01.ajg.0000578336.45781.9d","article-title":"The relationship between serum adalimumab and corresponding anti-adalimumab antibody levels: analysis of over 20,000 patient results","volume":"114","author":"Kelly","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.gendis.2020.02.004_bib28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/0091270009340782","article-title":"Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects","volume":"50","author":"Xu","year":"2010","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clinthera.2011.11.015","article-title":"Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study","volume":"34","author":"Zhuang","year":"2012","journal-title":"Clin Therapeut"},{"issue":"6","key":"10.1016\/j.gendis.2020.02.004_bib30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gendis.2020.02.004_bib31","doi-asserted-by":"crossref","first-page":"S437","DOI":"10.14309\/00000434-200609001-01117","article-title":"Investigation of the pharmacokinetic properties of certolizumab pegol, an anti-TNF agent: 1117","volume":"101","author":"Baker","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.gendis.2020.02.004_bib32","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/ard.2008.099291","article-title":"Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study","volume":"68","author":"Fleischmann","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.gendis.2020.02.004_bib33","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.23964","article-title":"Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"58","author":"Keystone","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib34","doi-asserted-by":"crossref","first-page":"e245","DOI":"10.1186\/s13075-015-0767-2","article-title":"Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients","volume":"17","author":"Smolen","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.gendis.2020.02.004_bib36","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.gendis.2020.02.004_bib37","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard.2009.121491","article-title":"Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study","volume":"69","author":"Tanaka","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.gendis.2020.02.004_bib38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.4161\/mabs.2.6.13583","article-title":"ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody","volume":"2","author":"Zettlitz","year":"2010","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib39","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/19420862.2018.1524664","article-title":"Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activity","volume":"11","author":"Richter","year":"2019","journal-title":"mAbs"},{"key":"10.1016\/j.gendis.2020.02.004_bib40","series-title":"Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc","author":"Richter","year":"2019"},{"issue":"17","key":"10.1016\/j.gendis.2020.02.004_bib41","doi-asserted-by":"crossref","first-page":"12526","DOI":"10.1016\/S0021-9258(18)31420-0","article-title":"Suramin induces deoligomerization of human tumor necrosis factor alpha","volume":"268","author":"Alzani","year":"1993","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.gendis.2020.02.004_bib42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0006-2952(99)00150-1","article-title":"Inhibition of tumor necrosis factor-alpha (TNF-alpha)\/TNF-alpha receptor binding by structural analogues of suramin","volume":"58","author":"Mancini","year":"1999","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.gendis.2020.02.004_bib43","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.bcp.2009.01.001","article-title":"Suramin inhibits the CD40-CD154 costimulatory interaction: a possible mechanism for immunosuppressive effects","volume":"77","author":"Margolles-Clark","year":"2009","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib44","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.intimp.2011.12.003","article-title":"Suramin ameliorates collagen induced arthritis","volume":"12","author":"Sahu","year":"2012","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cyto.2005.11.012","article-title":"Suramin prevents fulminant hepatic failure resulting in reduction of lethality through the suppression of NF-kappaB activity","volume":"33","author":"Goto","year":"2006","journal-title":"Cytokine"},{"issue":"5750","key":"10.1016\/j.gendis.2020.02.004_bib46","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1126\/science.1116304","article-title":"Small-molecule inhibition of TNF-alpha","volume":"310","author":"He","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pep.2013.04.005","article-title":"A statistical approach for optimization of RANKL overexpression in Escherichia coli: purification and characterization of the protein","volume":"90","author":"Papaneophytou","year":"2013","journal-title":"Protein Expr Purif"},{"issue":"4","key":"10.1016\/j.gendis.2020.02.004_bib48","doi-asserted-by":"crossref","first-page":"e1005372","DOI":"10.1371\/journal.pcbi.1005372","article-title":"Cheminformatics-aided discovery of small-molecule protein-protein interaction (PPI) dual inhibitors of tumor necrosis factor (TNF) and receptor activator of NF-kappaB ligand (RANKL)","volume":"13","author":"Melagraki","year":"2017","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib49","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/HYPERTENSIONAHA.119.12651","article-title":"Brain TACE (tumor necrosis factor-alpha-converting enzyme) contributes to sympathetic excitation in heart failure rats","volume":"74","author":"Yu","year":"2019","journal-title":"Hypertension"},{"issue":"8","key":"10.1016\/j.gendis.2020.02.004_bib50","doi-asserted-by":"crossref","first-page":"661","DOI":"10.2174\/1568026618666180607084430","article-title":"Current status and future prospects of small-molecule protein-protein interaction (PPI) inhibitors of tumor necrosis factor (TNF) and receptor activator of NF-kappaB ligand (RANKL)","volume":"18","author":"Melagraki","year":"2018","journal-title":"Curr Top Med Chem"},{"issue":"21","key":"10.1016\/j.gendis.2020.02.004_bib51","doi-asserted-by":"crossref","first-page":"11879","DOI":"10.1073\/pnas.211178398","article-title":"Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-alpha","volume":"98","author":"Carter","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.gendis.2020.02.004_bib52","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1007\/s00216-016-9633-6","article-title":"Identification of a ligand for tumor necrosis factor receptor from Chinese herbs by combination of surface plasmon resonance biosensor and UPLC-MS","volume":"408","author":"Cao","year":"2016","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib53","doi-asserted-by":"crossref","first-page":"e3424","DOI":"10.1038\/s41598-017-03427-z","article-title":"Identification of an in\u00a0vivo orally active dual-binding protein-protein interaction inhibitor targeting TNFalpha through combined in silico\/in\u00a0vitro\/in\u00a0vivo screening","volume":"7","author":"Mouhsine","year":"2017","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.gendis.2020.02.004_bib54","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/nbt1197-1266","article-title":"Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor","volume":"15","author":"Takasaki","year":"1997","journal-title":"Nat Biotechnol"},{"issue":"31","key":"10.1016\/j.gendis.2020.02.004_bib55","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.0504301102","article-title":"Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107","volume":"102","author":"Murali","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.gendis.2020.02.004_bib56","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1186\/s12974-018-1200-y","article-title":"Novel TNF receptor-1 inhibitors identified as potential therapeutic candidates for traumatic brain injury","volume":"15","author":"Rowe","year":"2018","journal-title":"J Neuroinflammation"}],"container-title":["Genes &amp; Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304220300349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304220300349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:26:33Z","timestamp":1762449993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304220300349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S2352304220300349"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2020.02.004","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of TNF\u03b1 inhibitors in chronic inflammatory disorders: Past and future","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2020.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Chongqing Medical University. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}